At a glance
ClinicalIndex Comparison RecordN/ACompleted· 244 enrolled
Drug / intervention
Lenvatinib + PD-1 monoclonal antibody +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and PD-1 Inhibitors Versus Lenvatinib Plus PD-1 Inhibitors as First-line Treatment for High Tumor Burden Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Target Trial Emulation Study
In Brief
An observational study evaluating hepatic artery infusion chemotherapy and Lenvatinib + PD-1 monoclonal antibody for HCC - Hepatocellular Carcinoma and 4 related conditions. Completed, enrolled 244 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitors
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedOct 2024
Primary CompletionOct 2025
TodayJul 2026
First PostedOct 8, 2024
Enrollment StartJan 1, 2021
Primary CompletionOct 22, 2025
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 1.7 years ago
Interventions
hepatic artery infusion chemotherapyprocedure
Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
Lenvatinib + PD-1 monoclonal antibodydrug
PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab